Abbott missed analysts' estimates for third-quarter revenue on Wednesday, as weakness in its diagnostics and nutritional ...

Abbott reported higher quarterly revenue on Wednesday, driven by strong demand for its medical devices including continuous ...

Abbott trimmed its earnings forecast as the Trump administration launched an investigation into medical device imports that ...

Abbott's quarterly revenue fell short of analysts' expectations on Wednesday, as weakness in its diagnostics and nutritional businesses failed to offset strong demand for its medical devices.

Abbott Laboratories cut the top end of its 2025 earnings guidance by 2 cents a share, just as the Trump administration ...

On an adjusted basis, Abbott reported third-quarter profit per share of $1.30, in line with analysts' average estimate. The ...

Get key Q3 2025 earnings insights for Abbott Labs (ABT)—discover growth drivers, innovation highlights, and outlook for 2026.

Abbott Laboratories ( NYSE: ABT) Q3 2025 Earnings Call October 15, 2025 9:00 AM EDT ...

The ACHIEVE-5 trial (ClinicalTrials.gov identifier: NCT06109311) was a randomized, double-blind, placebo-controlled study that included 546 T2D patients with inadequate glycemic control on insulin ...

New hypertension guidelines from the American Heart Association (AHA) and the American College of Cardiology mark a crucial ...

DOR/ISL data presented show minimal changes in weight and body composition and no clinically meaningful effect on fasting lipids and the homeostatic model assessment of insulin resistance (HOMA-IR) ...

KDIGO's new IgA nephropathy guideline shifts the treatment paradigm from supportive care alone to targeting the disease's immunologic nature.